AriBio Reports Mixed Phase 3 Results for Oral AR1001 in Early Alzheimer’s Disease

AR1001 met the primary endpoint in the prespecified Monotherapy population, with a CDR-SB treatment difference of -0.44 points versus placebo at Week 52 (p...

November 18, 2026 | Wednesday | News
Aclaris Therapeutics Initiates Phase 2b Trial of Modzatinib for Moderate-to-Severe Lichen Planus

Dual Inhibition of ITK and JAK3 Provides Potential for Modzatinib to be the First Mechanistically Complete Oral Therapy for Lichen Planus, an Unaddressed I...

November 17, 2026 | Tuesday | News
Novo Nordisk Seeks FDA and EMA Approval for Etavopivat to Treat Sickle Cell Disease

  The FDA New Drug Application (NDA) and EMA Marketing Authorization Application (MAA) submissions for etavopivat are based on da...

November 16, 2026 | Monday | News
Ascletis Pharma Submits US FDA IND Application for ASC30_39 Oral GLP-1 and Amylin Combination to Treat Obesity

ASC30_39 FDC, a once-daily oral fixed-dose combination (FDC) tablet of small molecule GLP-1R agonist ASC30 and small molecule selective amylin receptor ago...

November 12, 2026 | Thursday | News
NuNerve Advances NUN-004 into Phase 2 Trial for Motor Neurone Disease in Australia

An Australian-developed therapy aimed at halting the progression of motor neurone disease (MND) and restoring function by supporting the repair o...

November 11, 2026 | Wednesday | News
Suzhou Ribo Life Science Submits EU Phase 1 Trial Application for SR122 siRNA Therapy Targeting Lipid Disorders

Suzhou Ribo Life Science (06938.HK) and its subsidiary Ribocure Pharmaceuticals AB (collectively referred to as "Ribo") announced the submission of a Phase...

November 11, 2026 | Wednesday | News
Valneva Reports 94% Antibody Persistence Five Years After Single Dose of IXCHIQ Chikungunya Vaccine

94% of participants maintained seroresponse five years after a single vaccination Comparable antibody persistence observed in older (65+) and younger adul...

November 11, 2026 | Wednesday | News
GENFIT Advances Nangibotide Towards Phase 2 Trial for Acute-on-Chronic Liver Failure

Comprehensive clinical and scientific data supporting Phase 2 development of nangibotide in ACLF unveiled to leading experts during AASLD The Liver Meeting...

November 10, 2026 | Tuesday | News
Valneva Reports Positive Phase 2 Results for Shigella Vaccine S4V2 in Infants and Adults

Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, announced positive results from two Phase 2 trials of Shigella4V2 (S4V2), the ...

November 10, 2026 | Tuesday | News
Resalis Therapeutics Reports Early Weight-Loss Signals in Phase 1a Trial of RES-010 for Obesity

The completed Phase 1a study data in healthy volunteers showed early signs of pharmacodynamic activity supporting further clinical evaluation of RES-010 T...

November 06, 2026 | Friday | News
Ethris Reports 40-Fold Reduction in Viral Load in Phase 2a Trial of ETH47 for Asthma

40-fold lower virus load compared to placebo on Day 2, at the peak of viral replication Exposure-response relationship observed, with greater interferon l...

November 06, 2026 | Friday | News
TJ Biopharma Reports 83.3% Response Rate in Phase 2 Trial of Plonmarlimab for Macrophage Activation Syndrome

Findings build on TJ Biopharma's pioneering work on GM-CSF as a therapeutic target in macrophage- and myeloid cell-driven inflammation Phase 2 results s...

November 05, 2026 | Thursday | News
HUTCHMED and AstraZeneca Secure Regulatory Review in Europe and Japan for ORPATHYS and TAGRISSO Lung Cancer Combination

HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; HKEX:13) announces that regulatory filings for ORPATHYS® (savolitinib) in combinati...

November 03, 2026 | Tuesday | News
Heartflow Reports CT-Guided PCI Matches IVUS Outcomes with Shorter Procedures in 1,105-Patient P4 Trial

Late-Breaking P4 study, simultaneously published in NEJM, shows CT guidance delivers matched one-year clinical outcomes with shorter procedures, demonstrat...

November 03, 2026 | Tuesday | News

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
Processing...
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2026 Biopharma Boardroom. All Rights Reserved.

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close